{"id":185467,"date":"2025-11-17T15:23:06","date_gmt":"2025-11-17T15:23:06","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/185467\/"},"modified":"2025-11-17T15:23:06","modified_gmt":"2025-11-17T15:23:06","slug":"jj-expands-cancer-portfolio-with-3-05-billion-halda-buy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/185467\/","title":{"rendered":"J&J expands cancer portfolio with $3.05 billion Halda buy"},"content":{"rendered":"

Nov 17 (Reuters) – Johnson & Johnson (JNJ.N), opens new tab<\/a> said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, expanding its presence in treatments targeting solid tumors and prostate cancer.This marks the medtech conglomerate’s second major deal this year, after its $14.6 billion<\/a> acquisition of neurological drug maker Intra-Cellular Therapies in January, reinforcing its strategy to expand higher-growth healthcare segments through new launches as it navigates the loss of exclusivity for its blockbuster immune disease treatment Stelara.<\/p>\n

Sign up here.<\/a><\/p>\n

J&J has also pursued multiple deals in recent years to strengthen its pharmaceuticals and medical devices units, including a $13.1 billion<\/a> purchase of Shockwave Medical in 2024.<\/p>\n

Halda’s lead drug candidate, HLD-0915, is in early to mid-stage development for the treatment of prostate cancer. The company also has several early-stage experimental treatments for breast, lung and other types of tumors.<\/p>\n

Its “innovative technology is designed to work even when cancers no longer respond to standard treatments using a novel mechanism that enables the selective killing of cancer cells,” said John Reed, executive vice president of pharmaceutical research and development at Johnson & Johnson.<\/p>\n

Halda’s RiPTAC technology works by linking a cancer marker to a protein essential for cell survival, selectively disabling that protein in cancer cells so they die while sparing the healthy ones.<\/p>\n

J&J expects the deal to close within the next few months.<\/p>\n

Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar<\/p>\n

Our Standards: The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n

Purchase Licensing Rights<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Nov 17 (Reuters) – Johnson & Johnson (JNJ.N), opens new tab said on Monday it would buy privately…\n","protected":false},"author":2,"featured_media":185468,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[275],"tags":[82519,82499,36586,84105,82500,104395,82795,82502,82559,82530,87652,82560,82531,87219,18,45748,87209,135,475,474,87211,94704,19,17,721,82506,82565,82524,87647,82494,2765,88228,88229,82510,83002,82558,87204,87203,82533,107,93085],"class_list":["post-185467","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-amers","tag-bact","tag-biz","tag-blr","tag-cmpny","tag-cncer","tag-cprod","tag-deal1","tag-destlita","tag-destocabsm","tag-destohlt","tag-destoma","tag-destousbsm","tag-destoushem","tag-eire","tag-gen","tag-hea","tag-health","tag-health-care","tag-healthcare","tag-heca","tag-humdis","tag-ie","tag-ireland","tag-legal","tag-mrg","tag-mtpix","tag-namer","tag-nrlpaohlt","tag-nrlpaoma","tag-phar","tag-phar1","tag-phmr","tag-publ","tag-pxp","tag-reuters-legal","tag-rhpimergers-acquisitions","tag-topicpharma-healthcare-business-health","tag-topnws","tag-us","tag-xpand"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115565730521253238","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/185467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=185467"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/185467\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/185468"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=185467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=185467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=185467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}